Surgical treatment and prognosis of mesenchymal chondrosarcoma
10.3969/j.issn.1000-8179.20121855
- VernacularTitle:间叶性软骨肉瘤的外科治疗及预后分析
- Author:
Shun TANG
;
Wei GUO
;
Xiaodong TANG
;
Dasen LI
;
Yifei WANG
- Publication Type:Journal Article
- Keywords:
mesenchymal chondrosarcoma;
bone sarcoma;
prognosis;
surgery
- From:
Chinese Journal of Clinical Oncology
2013;(16):984-987
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To assess the surgical outcome of patients with mesenchymal chondrosarcoma (MCS) treated in our insti-tute. This study was also designed to describe the clinical characteristics, treatment, and outcome of MCS to provide a better understand-ing of its clinical management. Methods:A total of 27 patients with MCS were treated in Peking University People's Hospital, Beijing, China from October 1997 to March 2011. Demographic information and follow-up data were obtained and statistically analyzed. Re-sults:Among the 27 patients, 9 were males and 18 were females with a mean age of 30.4 years (ranging from 14 years to 51 years). The median follow-up time was 42.6 months (ranging from 6 months to 104 months). Among the total number of tumor cases, 22 and 5 were detected in bone tissues and extra-skeletal sites, respectively. A total of 25 patients underwent surgery, but only 17 achieved the standard surgical margin of wide excision. Among these patients, 16 and 13 were subjected to chemotherapy and irradiation. The three-and five-year survival rates were 65%and 49.5%, respectively. Conclusion:MCS is a rare tumor resulting in morbidity with local recur-rences and long-term metastases. In this study, standard multimodal regimens were proposed to treat MCS. The results recommended wide resection with suitable surgical margins as the preferred treatment. However, further studies should be conducted because the infor-mation about the benefits of chemotherapy and radiotherapy for the control of local or systemic symptoms of MCS remains insufficient.
